Alkermes Plc (ALKS NASDAQ) stock market data APIs
$45.0986
-0.3(-0.7%)
as of September 9, 2026
Try our APIs with
free plan!
Alkermes Plc Financial Data Overview
Price chart is built with
Anychart
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Prev. Close
45.0986
Open
44.7998
High
45.2033
Low
44.4141
52 wk Range
26.4-55.67
Market Cap
7 616 M
P/E Ratio
119.4737
Shares Outstanding
168 M
Revenue
1 668 M
EPS
0.52
Beta
0.26
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Alkermes Plc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Alkermes Plc data using free add-ons & libraries
Get Alkermes Plc Fundamental Data
Alkermes Plc Fundamental data includes:
- Net Revenue: 1 668 M
- EBITDA: 285 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-07-28
- EPS/Forecast: -0.04
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Alkermes Plc News
New
Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000
Christian Todd Nichols, SVP and Chief Commercial Officer of Alkermes (NASDAQ:ALKS), reported a sale of 7,576 shares of the company on Aug. 17, 2026, according to a recent SEC Form 4 filing. Transacti...
Why Is Alkermes (ALKS) Up 1.7% Since Last Earnings Report?
It has been about a month since the last earnings report for Alkermes (ALKS). Shares have added about 1.7% in that time frame, underperforming the S&P 500. But investors have to be wondering, will th...
The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
– Alixorexton Demonstrated Statistically Significant and Clinically Meaningful Improvements in Wakefulness and Cataplexy – – At All Doses Tested, Alixorexton Demonstrated Clinically Meaningful ...
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
Indivior Pharmaceuticals INDV agreed in August to combine with Supernus Pharmaceuticals SUPN in an all-stock merger of equals. The deal would shift Indivior from a business centered on opioid use diso...
Get Alkermes Plc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
